| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Enterobacteriaceae Infections | 4 | 2018 | 529 | 1.11 | Why? |
| Enterococcus | 3 | 2017 | 73 | 1.03 | Why? |
| Anti-Bacterial Agents | 31 | 2021 | 10083 | 1.01 | Why? |
| Drug Utilization | 8 | 2019 | 619 | 0.91 | Why? |
| Vancomycin Resistance | 2 | 2017 | 55 | 0.86 | Why? |
| Drug Resistance, Bacterial | 9 | 2021 | 1414 | 0.83 | Why? |
| Colistin | 3 | 2019 | 217 | 0.81 | Why? |
| Bacteriological Techniques | 3 | 2018 | 239 | 0.78 | Why? |
| Carbapenems | 3 | 2018 | 343 | 0.75 | Why? |
| Acinetobacter | 1 | 2018 | 58 | 0.75 | Why? |
| Drug Resistance, Microbial | 6 | 2019 | 419 | 0.69 | Why? |
| beta-Lactam Resistance | 1 | 2018 | 150 | 0.67 | Why? |
| Polymyxins | 1 | 2016 | 8 | 0.65 | Why? |
| Gram-Positive Bacterial Infections | 4 | 2017 | 323 | 0.62 | Why? |
| Enterobacteriaceae | 3 | 2018 | 395 | 0.62 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 214 | 0.61 | Why? |
| Acinetobacter Infections | 1 | 2018 | 273 | 0.59 | Why? |
| Plasmids | 1 | 2016 | 840 | 0.48 | Why? |
| Bacterial Proteins | 6 | 2019 | 1318 | 0.44 | Why? |
| Pneumonia, Bacterial | 4 | 2019 | 843 | 0.43 | Why? |
| Enterococcus faecium | 2 | 2017 | 95 | 0.42 | Why? |
| Practice Patterns, Physicians' | 8 | 2018 | 4927 | 0.42 | Why? |
| Drug Prescriptions | 4 | 2019 | 1062 | 0.40 | Why? |
| Respiratory Tract Infections | 10 | 2021 | 6817 | 0.39 | Why? |
| Pseudomonas aeruginosa | 5 | 2017 | 652 | 0.38 | Why? |
| Europe | 23 | 2021 | 12702 | 0.36 | Why? |
| Urinary Tract Infections | 3 | 2019 | 534 | 0.36 | Why? |
| Public Opinion | 2 | 2020 | 1165 | 0.35 | Why? |
| Antifungal Agents | 1 | 2017 | 1828 | 0.32 | Why? |
| Research Personnel | 1 | 2017 | 1037 | 0.32 | Why? |
| Swine Diseases | 1 | 2016 | 1219 | 0.30 | Why? |
| Herpesvirus 3, Human | 2 | 2017 | 228 | 0.29 | Why? |
| Oseltamivir | 2 | 2020 | 583 | 0.29 | Why? |
| Belgium | 9 | 2022 | 2064 | 0.28 | Why? |
| Inappropriate Prescribing | 2 | 2018 | 284 | 0.28 | Why? |
| Bacterial Infections | 8 | 2018 | 2229 | 0.25 | Why? |
| Immunotherapy, Adoptive | 2 | 2018 | 524 | 0.25 | Why? |
| Anti-Infective Agents | 3 | 2019 | 1766 | 0.24 | Why? |
| Klebsiella pneumoniae | 2 | 2019 | 658 | 0.24 | Why? |
| Pneumococcal Vaccines | 2 | 2018 | 571 | 0.23 | Why? |
| Carbon-Oxygen Ligases | 2 | 2017 | 9 | 0.23 | Why? |
| Virulence Factors | 1 | 2004 | 338 | 0.23 | Why? |
| Pneumococcal Infections | 2 | 2018 | 562 | 0.22 | Why? |
| Bacteria | 5 | 2019 | 1897 | 0.21 | Why? |
| Global Health | 5 | 2018 | 13911 | 0.21 | Why? |
| Glycopeptides | 2 | 2000 | 199 | 0.21 | Why? |
| Nitrofurantoin | 1 | 2019 | 14 | 0.21 | Why? |
| Amoxicillin | 2 | 2017 | 98 | 0.21 | Why? |
| Pseudomonas Infections | 2 | 2017 | 425 | 0.20 | Why? |
| Molecular Diagnostic Techniques | 4 | 2020 | 4239 | 0.20 | Why? |
| Communication | 2 | 2018 | 5206 | 0.20 | Why? |
| Microbial Sensitivity Tests | 8 | 2019 | 2886 | 0.20 | Why? |
| Biostatistics | 1 | 2020 | 116 | 0.20 | Why? |
| Agar | 1 | 2017 | 15 | 0.18 | Why? |
| Disk Diffusion Antimicrobial Tests | 1 | 2017 | 36 | 0.18 | Why? |
| Dendritic Cells | 2 | 2017 | 1330 | 0.18 | Why? |
| Immediate-Early Proteins | 1 | 2017 | 44 | 0.18 | Why? |
| Heparin | 2 | 2021 | 2600 | 0.18 | Why? |
| Secondary Care Centers | 1 | 2018 | 119 | 0.18 | Why? |
| Pneumonia, Staphylococcal | 1 | 2017 | 38 | 0.18 | Why? |
| Outpatients | 5 | 2019 | 3417 | 0.17 | Why? |
| Phagocytes | 1 | 2018 | 180 | 0.17 | Why? |
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2018 | 203 | 0.17 | Why? |
| Microbial Interactions | 1 | 2017 | 67 | 0.17 | Why? |
| Chickenpox | 2 | 2017 | 194 | 0.17 | Why? |
| Primary Health Care | 7 | 2021 | 4839 | 0.16 | Why? |
| Adaptive Immunity | 2 | 2020 | 2585 | 0.16 | Why? |
| Epidemiologic Methods | 1 | 2020 | 392 | 0.16 | Why? |
| Drug Resistance, Multiple, Bacterial | 3 | 2019 | 1115 | 0.16 | Why? |
| Pragmatic Clinical Trials as Topic | 1 | 2018 | 350 | 0.16 | Why? |
| Genetic Engineering | 1 | 2018 | 325 | 0.16 | Why? |
| Interleukin-4 | 1 | 2018 | 367 | 0.16 | Why? |
| Community-Acquired Infections | 2 | 2020 | 2328 | 0.16 | Why? |
| Trans-Activators | 1 | 2017 | 170 | 0.16 | Why? |
| Intraabdominal Infections | 1 | 2017 | 90 | 0.16 | Why? |
| Staphylococcus aureus | 3 | 2017 | 844 | 0.16 | Why? |
| Interleukin-15 | 1 | 2017 | 169 | 0.15 | Why? |
| Antibiotic Prophylaxis | 1 | 2019 | 399 | 0.15 | Why? |
| HLA-A Antigens | 1 | 2017 | 196 | 0.15 | Why? |
| Neural Stem Cells | 1 | 2017 | 135 | 0.15 | Why? |
| Carrier State | 2 | 2018 | 2100 | 0.15 | Why? |
| Cancer Vaccines | 1 | 2017 | 136 | 0.15 | Why? |
| Escherichia coli Infections | 1 | 2019 | 348 | 0.15 | Why? |
| Streptococcus pneumoniae | 2 | 2018 | 827 | 0.15 | Why? |
| Vancomycin | 1 | 1998 | 328 | 0.15 | Why? |
| Cost-Benefit Analysis | 4 | 2018 | 2259 | 0.15 | Why? |
| Humans | 79 | 2022 | 930598 | 0.14 | Why? |
| Polymerase Chain Reaction | 4 | 2019 | 6740 | 0.14 | Why? |
| Physicians, Primary Care | 1 | 2018 | 298 | 0.14 | Why? |
| Intestines | 2 | 2000 | 817 | 0.14 | Why? |
| Culture Media | 1 | 1997 | 366 | 0.14 | Why? |
| Staphylococcus | 1 | 1995 | 77 | 0.14 | Why? |
| Escherichia coli | 3 | 2019 | 1547 | 0.14 | Why? |
| Molecular Biology | 1 | 1997 | 139 | 0.14 | Why? |
| Influenza, Human | 4 | 2020 | 10779 | 0.14 | Why? |
| Truth Disclosure | 1 | 2017 | 196 | 0.14 | Why? |
| Macrophages, Alveolar | 1 | 2018 | 668 | 0.13 | Why? |
| Klebsiella Infections | 1 | 2019 | 466 | 0.13 | Why? |
| Education | 1 | 2018 | 434 | 0.13 | Why? |
| Prevalence | 10 | 2020 | 25773 | 0.13 | Why? |
| Seasons | 3 | 2020 | 4071 | 0.13 | Why? |
| Housing | 1 | 2021 | 1146 | 0.12 | Why? |
| European Union | 1 | 2017 | 565 | 0.12 | Why? |
| Viral Envelope Proteins | 2 | 2017 | 3539 | 0.12 | Why? |
| Quality Indicators, Health Care | 1 | 2018 | 580 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2021 | 1383 | 0.12 | Why? |
| Candidiasis | 1 | 1997 | 334 | 0.12 | Why? |
| Candida | 1 | 1997 | 425 | 0.12 | Why? |
| Antimicrobial Stewardship | 2 | 2019 | 931 | 0.12 | Why? |
| Health Policy | 1 | 2013 | 6242 | 0.12 | Why? |
| Herpes Zoster | 1 | 2017 | 331 | 0.12 | Why? |
| Hospital Bed Capacity | 1 | 2020 | 1300 | 0.12 | Why? |
| Pneumonia | 4 | 2020 | 5652 | 0.12 | Why? |
| Cross Infection | 3 | 2019 | 8675 | 0.11 | Why? |
| Coronavirus | 5 | 2020 | 18339 | 0.11 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 711 | 0.11 | Why? |
| Staphylococcal Infections | 2 | 2018 | 1099 | 0.11 | Why? |
| Epithelial Cells | 2 | 2014 | 3508 | 0.11 | Why? |
| Central Nervous System | 1 | 2017 | 701 | 0.11 | Why? |
| Virus Cultivation | 1 | 2014 | 579 | 0.11 | Why? |
| beta-Lactamase Inhibitors | 1 | 2012 | 104 | 0.11 | Why? |
| RNA | 1 | 2018 | 1278 | 0.11 | Why? |
| Azabicyclo Compounds | 1 | 2012 | 91 | 0.11 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 533 | 0.11 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2017 | 676 | 0.10 | Why? |
| Ceftazidime | 1 | 2012 | 134 | 0.10 | Why? |
| Hydrocortisone | 1 | 2020 | 1790 | 0.10 | Why? |
| Anticoagulants | 2 | 2021 | 9563 | 0.10 | Why? |
| Diagnostic Tests, Routine | 2 | 2018 | 2643 | 0.10 | Why? |
| Thrombosis | 2 | 2021 | 7504 | 0.09 | Why? |
| Nasopharynx | 2 | 2019 | 10224 | 0.09 | Why? |
| Electroporation | 2 | 2018 | 52 | 0.09 | Why? |
| Health Care Surveys | 4 | 2019 | 2942 | 0.09 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.09 | Why? |
| Reagent Kits, Diagnostic | 2 | 2019 | 2149 | 0.09 | Why? |
| Point-of-Care Systems | 2 | 2020 | 2955 | 0.09 | Why? |
| Poland | 3 | 2021 | 2368 | 0.09 | Why? |
| Northern Ireland | 2 | 2018 | 228 | 0.09 | Why? |
| Membrane Proteins | 1 | 2018 | 1733 | 0.09 | Why? |
| Male | 29 | 2021 | 367725 | 0.09 | Why? |
| Middle Aged | 24 | 2021 | 270681 | 0.09 | Why? |
| Reference Standards | 1 | 2011 | 1163 | 0.08 | Why? |
| Endpoint Determination | 2 | 2020 | 344 | 0.08 | Why? |
| Female | 29 | 2021 | 380317 | 0.08 | Why? |
| Streptogramins | 1 | 2006 | 2 | 0.08 | Why? |
| Cough | 2 | 2018 | 4891 | 0.08 | Why? |
| Killer Cells, Natural | 1 | 2017 | 2093 | 0.08 | Why? |
| Quality Assurance, Health Care | 1 | 2011 | 596 | 0.08 | Why? |
| Aged | 19 | 2021 | 215776 | 0.08 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.08 | Why? |
| Ritonavir | 1 | 2021 | 4212 | 0.08 | Why? |
| World Health Organization | 1 | 2019 | 4213 | 0.08 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.08 | Why? |
| Orthomyxoviridae | 1 | 2014 | 1168 | 0.08 | Why? |
| Respiratory Mucosa | 1 | 2014 | 1522 | 0.08 | Why? |
| Adult | 20 | 2021 | 244371 | 0.07 | Why? |
| Young Adult | 11 | 2021 | 93724 | 0.07 | Why? |
| Quality Improvement | 1 | 2018 | 2435 | 0.07 | Why? |
| Adolescent | 11 | 2021 | 86841 | 0.07 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 1 | 2004 | 78 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2017 | 4545 | 0.07 | Why? |
| Netherlands | 3 | 2021 | 3533 | 0.07 | Why? |
| Time Factors | 8 | 2020 | 31397 | 0.07 | Why? |
| Point-of-Care Testing | 1 | 2018 | 2782 | 0.07 | Why? |
| C-Reactive Protein | 2 | 2018 | 7972 | 0.07 | Why? |
| Immunization Programs | 1 | 2017 | 2006 | 0.07 | Why? |
| Viral Tropism | 1 | 2013 | 1329 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2018 | 5837 | 0.07 | Why? |
| Child, Preschool | 6 | 2021 | 36283 | 0.07 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.07 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.07 | Why? |
| Cephalosporins | 1 | 2006 | 250 | 0.07 | Why? |
| Coronavirus 229E, Human | 1 | 2012 | 1241 | 0.07 | Why? |
| Research | 1 | 2017 | 2115 | 0.07 | Why? |
| Infant | 5 | 2021 | 30274 | 0.06 | Why? |
| Pediatrics | 1 | 2019 | 2969 | 0.06 | Why? |
| Internet | 2 | 2018 | 6204 | 0.06 | Why? |
| Hospitals | 5 | 2021 | 11793 | 0.06 | Why? |
| Membrane Glycoproteins | 1 | 2012 | 2273 | 0.06 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.06 | Why? |
| Molecular Epidemiology | 2 | 2018 | 1638 | 0.06 | Why? |
| Respiration, Artificial | 4 | 2021 | 22116 | 0.06 | Why? |
| Animals | 7 | 2018 | 78931 | 0.06 | Why? |
| Surveys and Questionnaires | 6 | 2020 | 43792 | 0.06 | Why? |
| Immunoassay | 1 | 2019 | 4485 | 0.06 | Why? |
| Macrolides | 1 | 2006 | 369 | 0.06 | Why? |
| Renal Dialysis | 1 | 2000 | 4358 | 0.06 | Why? |
| Child | 8 | 2021 | 70012 | 0.06 | Why? |
| Virus Diseases | 3 | 2017 | 3779 | 0.06 | Why? |
| Vaccination | 2 | 2018 | 19050 | 0.06 | Why? |
| Armenia | 1 | 2021 | 89 | 0.06 | Why? |
| Sensitivity and Specificity | 5 | 2020 | 22971 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.06 | Why? |
| General Practitioners | 2 | 2018 | 568 | 0.05 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.05 | Why? |
| Disease Progression | 2 | 2017 | 13580 | 0.05 | Why? |
| Pandemics | 13 | 2021 | 389249 | 0.05 | Why? |
| Influenza B virus | 2 | 2019 | 815 | 0.05 | Why? |
| Multicenter Studies as Topic | 2 | 2018 | 2437 | 0.05 | Why? |
| Acute Disease | 3 | 2018 | 6029 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Gentamicins | 1 | 2000 | 76 | 0.05 | Why? |
| Nursing Homes | 1 | 2017 | 4155 | 0.05 | Why? |
| Antiviral Agents | 4 | 2021 | 41703 | 0.05 | Why? |
| India | 2 | 2018 | 11875 | 0.05 | Why? |
| beta-Lactamases | 2 | 2019 | 759 | 0.05 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.05 | Why? |
| Ribonuclease III | 1 | 2018 | 45 | 0.05 | Why? |
| T-Cell Antigen Receptor Specificity | 1 | 2018 | 93 | 0.05 | Why? |
| International Cooperation | 1 | 2013 | 3436 | 0.05 | Why? |
| Germany | 3 | 2021 | 9196 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.05 | Why? |
| Hemorrhage | 2 | 2021 | 3013 | 0.05 | Why? |
| Nitrofurans | 1 | 2018 | 5 | 0.05 | Why? |
| Genes, Bacterial | 1 | 2000 | 207 | 0.05 | Why? |
| Evolution, Molecular | 1 | 2012 | 3691 | 0.05 | Why? |
| Headache | 2 | 2020 | 2257 | 0.05 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
| Consensus Development Conferences as Topic | 1 | 2018 | 93 | 0.05 | Why? |
| WT1 Proteins | 1 | 2017 | 15 | 0.04 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.04 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.04 | Why? |
| Infant, Newborn | 4 | 2021 | 23105 | 0.04 | Why? |
| Pneumocystis Infections | 1 | 1997 | 10 | 0.04 | Why? |
| beta-Galactosidase | 1 | 1997 | 40 | 0.04 | Why? |
| Inpatients | 3 | 2018 | 5161 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2020 | 536 | 0.04 | Why? |
| Nonprescription Drugs | 1 | 2018 | 78 | 0.04 | Why? |
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2017 | 72 | 0.04 | Why? |
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2017 | 64 | 0.04 | Why? |
| DNA Fingerprinting | 1 | 1997 | 41 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2018 | 264 | 0.04 | Why? |
| Grandparents | 1 | 2017 | 21 | 0.04 | Why? |
| Drug Resistance, Multiple | 1 | 1998 | 156 | 0.04 | Why? |
| Treatment Outcome | 6 | 2020 | 51732 | 0.04 | Why? |
| DNA, Fungal | 1 | 1997 | 95 | 0.04 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2011 | 3388 | 0.04 | Why? |
| Kaplan-Meier Estimate | 2 | 2017 | 4260 | 0.04 | Why? |
| Early Termination of Clinical Trials | 1 | 2020 | 1256 | 0.04 | Why? |
| Penicillins | 1 | 2018 | 132 | 0.04 | Why? |
| Drug Combinations | 2 | 2021 | 3852 | 0.04 | Why? |
| Virulence | 1 | 2004 | 2172 | 0.04 | Why? |
| Prospective Studies | 6 | 2022 | 43301 | 0.04 | Why? |
| Cytotoxicity, Immunologic | 1 | 2018 | 287 | 0.04 | Why? |
| Antigens, Neoplasm | 1 | 2018 | 230 | 0.04 | Why? |
| Disease Vectors | 1 | 1998 | 208 | 0.04 | Why? |
| Vesicular Transport Proteins | 1 | 2017 | 110 | 0.04 | Why? |
| Otitis Media | 1 | 2017 | 106 | 0.04 | Why? |
| Animals, Domestic | 1 | 1998 | 272 | 0.04 | Why? |
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 102 | 0.04 | Why? |
| United Kingdom | 1 | 2017 | 18046 | 0.04 | Why? |
| Fluoroquinolones | 1 | 2018 | 235 | 0.04 | Why? |
| Economics | 1 | 2018 | 196 | 0.04 | Why? |
| Rats, Wistar | 1 | 2018 | 621 | 0.04 | Why? |
| Health Personnel | 3 | 2022 | 29646 | 0.04 | Why? |
| Antibodies, Viral | 2 | 2020 | 51949 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Ireland | 1 | 2021 | 1456 | 0.04 | Why? |
| Jordan | 1 | 2018 | 701 | 0.04 | Why? |
| Coagulase | 1 | 1995 | 44 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.04 | Why? |
| Vaccines, Conjugate | 1 | 2018 | 328 | 0.04 | Why? |
| Delivery of Health Care | 2 | 2021 | 15909 | 0.04 | Why? |
| Laboratories, Hospital | 1 | 2020 | 489 | 0.04 | Why? |
| Cohort Studies | 4 | 2022 | 36005 | 0.04 | Why? |
| Child Day Care Centers | 1 | 2017 | 208 | 0.04 | Why? |
| Child, Hospitalized | 1 | 2019 | 556 | 0.04 | Why? |
| Serogroup | 1 | 2017 | 510 | 0.04 | Why? |
| Tidal Volume | 1 | 2018 | 565 | 0.04 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.04 | Why? |
| HIV Infections | 2 | 2020 | 11620 | 0.04 | Why? |
| Quality-Adjusted Life Years | 1 | 2018 | 511 | 0.04 | Why? |
| Prescription Drugs | 1 | 2018 | 243 | 0.04 | Why? |
| Cause of Death | 2 | 2020 | 4823 | 0.04 | Why? |
| Influenza A virus | 2 | 2019 | 2234 | 0.03 | Why? |
| Greece | 1 | 2021 | 2091 | 0.03 | Why? |
| North America | 1 | 2019 | 1400 | 0.03 | Why? |
| Sweden | 1 | 2021 | 1969 | 0.03 | Why? |
| Symptom Assessment | 2 | 2018 | 4967 | 0.03 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.03 | Why? |
| Bacterial Typing Techniques | 1 | 1995 | 273 | 0.03 | Why? |
| Genome, Viral | 2 | 2014 | 13157 | 0.03 | Why? |
| RNA, Small Interfering | 1 | 2018 | 817 | 0.03 | Why? |
| Return to Work | 1 | 2020 | 579 | 0.03 | Why? |
| Predictive Value of Tests | 3 | 2019 | 9537 | 0.03 | Why? |
| Remission Induction | 1 | 2017 | 950 | 0.03 | Why? |
| Evaluation Studies as Topic | 1 | 1995 | 391 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Candidiasis, Oral | 1 | 1993 | 58 | 0.03 | Why? |
| Clinical Laboratory Services | 1 | 2020 | 781 | 0.03 | Why? |
| Primary Cell Culture | 1 | 2014 | 501 | 0.03 | Why? |
| Hospitalization | 6 | 2020 | 54280 | 0.03 | Why? |
| Critical Illness | 3 | 2021 | 17281 | 0.03 | Why? |
| Age Factors | 3 | 2020 | 21039 | 0.03 | Why? |
| Cell Movement | 1 | 2017 | 695 | 0.03 | Why? |
| Genetic Drift | 1 | 2012 | 54 | 0.03 | Why? |
| Shock | 1 | 2020 | 1868 | 0.03 | Why? |
| Spatio-Temporal Analysis | 1 | 2019 | 1182 | 0.03 | Why? |
| Fluconazole | 1 | 1993 | 145 | 0.03 | Why? |
| Hospital Mortality | 3 | 2021 | 22087 | 0.03 | Why? |
| Decision Support Techniques | 1 | 2020 | 903 | 0.03 | Why? |
| History, 20th Century | 1 | 2019 | 1282 | 0.03 | Why? |
| Immunity, Herd | 1 | 2020 | 1011 | 0.03 | Why? |
| Risk Management | 1 | 2020 | 1044 | 0.03 | Why? |
| Drug Industry | 1 | 2020 | 689 | 0.03 | Why? |
| Cytopathogenic Effect, Viral | 1 | 2014 | 635 | 0.03 | Why? |
| Myalgia | 1 | 2018 | 1015 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Models, Immunological | 1 | 2017 | 727 | 0.03 | Why? |
| Fever | 2 | 2020 | 7795 | 0.03 | Why? |
| Imipenem | 1 | 2012 | 57 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.03 | Why? |
| History, 21st Century | 1 | 2019 | 1849 | 0.03 | Why? |
| Cytomegalovirus | 1 | 2017 | 600 | 0.03 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.03 | Why? |
| Bayes Theorem | 1 | 2021 | 3237 | 0.03 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.03 | Why? |
| Viruses | 2 | 2018 | 2238 | 0.03 | Why? |
| Eosinophils | 1 | 2018 | 848 | 0.03 | Why? |
| Genetic Vectors | 1 | 2018 | 1600 | 0.03 | Why? |
| Cells, Cultured | 2 | 2013 | 5835 | 0.03 | Why? |
| 3' Untranslated Regions | 1 | 2012 | 318 | 0.03 | Why? |
| Pharmacy Service, Hospital | 1 | 2019 | 645 | 0.03 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 1993 | 260 | 0.03 | Why? |
| Species Specificity | 1 | 1995 | 1356 | 0.03 | Why? |
| Health Services Accessibility | 3 | 2020 | 10697 | 0.03 | Why? |
| Feces | 1 | 2004 | 4235 | 0.03 | Why? |
| Chemokines | 1 | 2017 | 1095 | 0.03 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 11367 | 0.03 | Why? |
| Mycoses | 1 | 1997 | 589 | 0.03 | Why? |
| Rats | 1 | 2018 | 2764 | 0.03 | Why? |
| Self Care | 1 | 2018 | 918 | 0.02 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.02 | Why? |
| Switzerland | 1 | 2018 | 2738 | 0.02 | Why? |
| Observational Studies as Topic | 1 | 2017 | 1887 | 0.02 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.02 | Why? |
| Health Communication | 1 | 2020 | 1120 | 0.02 | Why? |
| Disease Models, Animal | 2 | 2018 | 10998 | 0.02 | Why? |
| England | 1 | 2021 | 5116 | 0.02 | Why? |
| Microfluidics | 1 | 2011 | 171 | 0.02 | Why? |
| Lung | 1 | 2018 | 31049 | 0.02 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 2309 | 0.02 | Why? |
| Coinfection | 2 | 2020 | 6820 | 0.02 | Why? |
| Qualitative Research | 1 | 2021 | 4337 | 0.02 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.02 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.02 | Why? |
| Sputum | 1 | 2016 | 1720 | 0.02 | Why? |
| Hospitals, Pediatric | 1 | 2019 | 1792 | 0.02 | Why? |
| Biological Assay | 1 | 2011 | 367 | 0.02 | Why? |
| Survival Analysis | 1 | 2021 | 7592 | 0.02 | Why? |
| Campylobacter | 1 | 1987 | 34 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.02 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2018 | 2262 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2018 | 5814 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2020 | 2844 | 0.02 | Why? |
| Singapore | 1 | 2017 | 3641 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2020 | 3228 | 0.02 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.02 | Why? |
| Lincosamides | 1 | 2006 | 23 | 0.02 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.02 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.02 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Sequence Alignment | 1 | 2012 | 2109 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2022 | 10017 | 0.02 | Why? |
| Streptococcus pyogenes | 1 | 1986 | 118 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Health Surveys | 1 | 2017 | 2841 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2019 | 3129 | 0.02 | Why? |
| Open Reading Frames | 1 | 2012 | 1898 | 0.02 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| General Surgery | 1 | 2017 | 1472 | 0.02 | Why? |
| Base Sequence | 1 | 2012 | 3581 | 0.02 | Why? |
| Canada | 1 | 2017 | 6018 | 0.02 | Why? |
| Australia | 1 | 2017 | 6306 | 0.02 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.02 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.02 | Why? |
| Streptococcal Infections | 1 | 1986 | 255 | 0.02 | Why? |
| Smoking | 1 | 2016 | 3358 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 3633 | 0.02 | Why? |
| Virus Replication | 2 | 2014 | 14331 | 0.01 | Why? |
| RNA, Viral | 2 | 2020 | 32276 | 0.01 | Why? |
| Pharyngitis | 1 | 1986 | 687 | 0.01 | Why? |
| High-Throughput Screening Assays | 1 | 2011 | 1783 | 0.01 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.01 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.01 | Why? |
| Medication Adherence | 1 | 2011 | 1270 | 0.01 | Why? |
| Amino Acid Sequence | 1 | 2012 | 6049 | 0.01 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2018 | 8248 | 0.01 | Why? |
| Respiratory System | 1 | 2013 | 3213 | 0.01 | Why? |
| Nucleocapsid Proteins | 1 | 2012 | 3120 | 0.01 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.01 | Why? |
| Mice | 2 | 2018 | 21357 | 0.01 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.01 | Why? |
| Radiography, Thoracic | 1 | 2016 | 5486 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2017 | 48226 | 0.01 | Why? |
| Genomics | 1 | 2011 | 3118 | 0.01 | Why? |
| Masks | 1 | 2021 | 8528 | 0.01 | Why? |
| Risk Factors | 2 | 2017 | 71621 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 8811 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.01 | Why? |
| Drug Discovery | 1 | 2011 | 3092 | 0.01 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.01 | Why? |
| Developing Countries | 1 | 2011 | 4283 | 0.01 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.01 | Why? |
| Phylogeny | 1 | 2012 | 13341 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2017 | 21571 | 0.01 | Why? |
| Comorbidity | 1 | 2016 | 34796 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| United States | 1 | 1998 | 46150 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.01 | Why? |
| Retrospective Studies | 1 | 2020 | 105322 | 0.01 | Why? |
| Germ-Free Life | 1 | 1987 | 63 | 0.01 | Why? |
| Latex Fixation Tests | 1 | 1986 | 8 | 0.01 | Why? |
| Campylobacter Infections | 1 | 1987 | 37 | 0.01 | Why? |
| Spleen | 1 | 1987 | 877 | 0.00 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2012 | 37182 | 0.00 | Why? |
| Pilot Projects | 1 | 1993 | 5182 | 0.00 | Why? |
| Lymph Nodes | 1 | 1987 | 1060 | 0.00 | Why? |
| Liver | 1 | 1987 | 4007 | 0.00 | Why? |